NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $9.24 +0.89 (+10.66%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$7.91▼$9.5650-Day Range$1.11▼$8.3552-Week Range$1.09▼$11.18Volume8.01 million shsAverage Volume2.59 million shsMarket Capitalization$21.33 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get GeoVax Labs alerts: Email Address GeoVax Labs MarketRank™ Stock AnalysisAnalyst RatingBuy3.40 Rating ScoreUpside/Downside51.7% Upside$12.67 Price TargetShort InterestHealthy3.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 25 Articles This WeekInsider TradingAcquiring Shares$15,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($7.41) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector193rd out of 924 stocksPharmaceutical Preparations Industry73rd out of 426 stocks 4.7 Analyst's Opinion Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GeoVax Labs' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.53% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 29.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GOVX. Previous Next 3.0 News and Social Media Coverage News SentimentGeoVax Labs has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for GeoVax Labs this week, compared to 1 article on an average week.Search Interest58 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 87% compared to the previous 30 days.MarketBeat Follows15 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($7.41) to ($1.75) per share.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About GeoVax Labs Stock (NASDAQ:GOVX)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVX Stock News HeadlinesAugust 20 at 9:29 AM | marketbeat.comGeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust? (GOVX)GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.August 13, 2024 | insidertrades.comGeoVax Labs, Inc. (NASDAQ:GOVX) CEO David A. Dodd Acquires 8,000 SharesAugust 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.August 21 at 7:43 PM | finanznachrichten.deGeoVax, Inc.: GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketAugust 21 at 7:43 PM | msn.comGeoVax Labs Stock Surges Ahead Of The Close, Shares Remain Volatile: What's Happening?August 21 at 10:59 AM | finance.yahoo.comRegistration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEOAugust 20 at 12:06 PM | msn.comGeoVax’s stock slides 26% after company raises $8.5 million in stock saleAugust 20 at 12:06 PM | msn.comGeoVax Stock Is Tumbling Tuesday: What's Going On?August 22, 2024 | TradingTips (Ad)5 stocks that can double in 2024You still have time to access the 5 Stocks that Can Double in 2024 report for free.August 20 at 9:05 AM | markets.businessinsider.comGeoVax Labs Offers $8.5 Mln Of Shares; Stock Down Over 25% In Pre-MarketAugust 20 at 7:45 AM | globenewswire.comGeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-MarketAugust 20 at 7:05 AM | finance.yahoo.comZacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutionsAugust 19 at 4:02 PM | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: GeoVax Labs (GOVX), Rohto Pharmaceutical Co (RPHCF)August 19 at 4:02 PM | benzinga.comGeoVax Labs Stock Continues To Surge: What's Going On?August 19 at 11:16 AM | americanbankingnews.comGeoVax Labs (NASDAQ:GOVX) Given New $10.00 Price Target at Noble FinancialAugust 19 at 7:50 AM | marketwatch.comGeoVax’s stock soars 54% to lead rally in companies developing mpox treatmentsAugust 18, 2024 | benzinga.comGeovax Labs (NASDAQ:GOVX) Stock Quotes, Forecast and News SummaryAugust 16, 2024 | benzinga.comGeovax Labs (NASDAQ:GOVX) Stock, Short Interest ReportSee More Headlines Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/22/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+51.7%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-346.15% Return on Assets-221.83% Debt Debt-to-Equity RatioN/A Current Ratio0.87 Quick Ratio0.87 Sales & Book Value Annual Sales$300,677.00 Price / Sales64.09 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book2.58Miscellaneous Outstanding Shares2,308,000Free Float2,176,000Market Cap$19.27 million OptionableNot Optionable Beta3.09 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 74)Chairman, President & CEO Comp: $384.2kDr. Mark J. Newman Ph.D. (Age 69)Chief Scientific Officer Comp: $291.5kDr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Comp: $361.03kDr. Harriet Latham Robinson Ph.D. (Age 86)Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board Mr. Thomas O'BrienVice President of Quality Systems & ComplianceMr. Jeffrey WelchHead of Process Development & Manufacturing OperationsDr. Valerie C. Montgomery Rice FACOG (Age 61)M.D., Special Advisor to the Chairman & CEO and Board of Directors Mr. John NilesHead of Commercial OperationsDr. John W. Sharkey Ph.D. (Age 68)Vice President of Business Development More ExecutivesKey CompetitorsVor BiopharmaNYSE:VORLeap TherapeuticsNASDAQ:LPTXTheratechnologiesNASDAQ:THTXConnect BiopharmaNASDAQ:CNTBPrecision BioSciencesNASDAQ:DTILView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 98,000 shares on 8/15/2024Ownership: 3.466%David A DoddBought 8,000 shares on 8/9/2024Total: $15,600.00 ($1.95/share)David A DoddBought 520 shares on 2/21/2024Total: $1,118.00 ($2.15/share)Kelly T Jr. MckeeBought 462 shares on 12/22/2023Total: $2,494.80 ($5.40/share)Kelly T Jr. MckeeBought 643 shares on 9/25/2023Total: $5,015.40 ($7.80/share)View All Insider TransactionsView All Institutional Transactions GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $5.4150 on January 1st, 2024. Since then, GOVX stock has increased by 54.2% and is now trading at $8.35. View the best growth stocks for 2024 here. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The firm earned $0.30 million during the quarter. When did GeoVax Labs' stock split? GeoVax Labs shares reverse split before market open on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are GeoVax Labs' major shareholders? GeoVax Labs' top institutional shareholders include Armistice Capital LLC (3.47%). Insiders that own company stock include David A Dodd, Mark Reynolds, Randal D Chase, Kelly T Jr Mckee and John W Sharkey. View institutional ownership trends. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOVX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredThis Crypto Is Set to Explode in AugustWith the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the...Crypto 101 Media | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThis One stock is all you need...What if you could ignore 99% of the stock market... And retire on just ONE ticker?Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
